Prasugrel

Molecular structure of Prasugrel  (CAS NO.150322-43-3) is:

Product Name: Prasugrel
CAS Registry Number: 150322-43-3
IUPAC Name: [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] acetate
Molecular Weight: 373.441103 [g/mol]
Molecular Formula: C₂₀H₂₀FNO₃S
XLogP3-AA: 3.6
H-Bond Donor: 0
H-Bond Acceptor: 5 
Surface Tension: 56.7 dyne/cm
Density: 1.347 g/cm³
Flash Point: 252.3 °C
Enthalpy of Vaporization: 76.06 kJ/mol
Boiling Point: 493.5 °C at 760 mmHg
Vapour Pressure: 7.01E-10 mmHg at 25°C
Classification Code: Platelet Aggregation Inhibitors

  Prasugrel (marketing name Effient in the US and Efient in EU) is a novel platelet inhibitor developed by Daiichi Sankyo Co. and produced by Ube and currently under clinical development in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). The U.S. Food and Drug Administration approved Effient tablets for the reduction of thrombotic cardiovascular events in July 10, 2009.

 Prasugrel (CAS NO.150322-43-3) can be used as a novel platelet inhibitor.And it is a P2Y(12) receptor antagonist with antiplatelet activity.

 Prasugrel , its cas register number is 150322-43-3. It also can be called 2-[2-(Acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)ethanone .It is a member of the thienopyridine class of ADP receptor inhibitors. And it produces inhibition of platelet aggregation to 20 μM or 5 μM ADP, as measured by light transmission aggregometry.